Drug Profile
Research programme: selective estrogen receptor beta agonists - Eli Lilly and Company
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Benzopyrans
- Mechanism of Action Selective estrogen receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 17 Apr 2007 Data presented at the 233rd American Chemical Society National Meeting (ACS-2007) added to the Men's Health pharmacodynamics section
- 29 Mar 2005 Preclinical trials in Cancer in USA (unspecified route)